In a study that compares rapid antigen and laboratory PCR approaches for COVID-19 serial screening, researchers affiliated with the NIH RADx initiative reported results from 43 people infected with the virus.
NIBIB-funded researchers are investigating long-lasting, customizable nanobubbles for ultrasound contrast agents.
University Hospitals in Cleveland is the global pioneer in full clinical adoption of GE Healthcare’s new Critical Care Suite 2.0, the world’s first on-device artificial intelligence program helping to assess endotracheal tube placement.
The NanoSpot.AI test is estimated to be significantly less expensive to manufacture than other SARS-CoV-2 antibody tests and has the potential to be more affordable than currently available tests, making it possible to extend the test to every corner of the world. Clinical studies validating NanoSpot.AI are currently underway.
A new grant is helping McMaster University engineers and a Toronto precision-medicine diagnostics company to get infection-testing technology to market while generating opportunities for students.
An artificial intelligence-enabled in vitro diagnostics company and the University of Utah today announced a partnership to improve kidney health and reduce the risk of kidney failure for large scale populations in the earliest stages of kidney disease.
A new, compact system has been successfully demonstrated at the Berkeley Lab Laser Accelerator (BELLA) Center to provide simultaneous high-resolution measurements of multiple electron-beam properties.
GenScript USA Inc., the world’s leading research reagent provider, announced today that Brazil’s National Health Surveillance Agency (ANVISA) (Agência Nacional de Vigilância Sanitária) has authorized the use of the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit for detecting neutralizing antibodies. The cPass test is the first and only ANVISA authorized test for detecting neutralizing antibodies to SARS-CoV-2. Neutralizing antibodies specifically block the ability of a virus to infect a cell and are well-recognized to confer immunity.
Researchers at Canada’s McMaster University and SQI Diagnostics have created a surface that repels every other element of human blood except a critical indicator of infection, opening a timely window for understanding the progress of COVID-19 in individual patients.
A team led by Professor Hossam Haick and Dr. Yoav Broza of the Technion Faculty of Chemical Engineering and Russell Berrie Nanotechnology Institute, in collaboration with researchers from Wuhan, China, has devised a novel breath analyzer test to rapidly detect COVID-19.
Nanoparticles are actively employed in medicine as contrast agents as well as for diagnosis and therapy of various diseases. However, the development of novel multifunctional nanoagents is impeded by the difficulty of monitoring their blood circulation. Researches from the Moscow Institute of Physics and Technology, the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of RAS, Moscow Engineering Physics Institute, Prokhorov General Physics Institute of RAS, and Sirius University have developed a new noninvasive method of nanoparticle measurement in the bloodstream that boasts a high time resolution. This technique has revealed the basic parameters that affect particle lifetime in the bloodstream, which may potentially lead to discovery of new, more effective nanoagents to be used in biomedicine.
A new center hosted at the University of Chicago — co-led by the largest medical imaging professional organizations in the country — will help tackle the ongoing COVID-19 pandemic by curating a massive database of medical images to help better understand and treat the disease. The work is supported by a $20 million, two-year federal contract that could be renewable to $50 million over five years.
Our ability to predict who will get cancer, how patients will respond to treatment, or if patients will relapse is still quite limited, despite advances in the detection of genetic mutations and the establishment of risk factors; recently researchers were inspired to find new ways of looking at the problem. In Biomicrofluidics, they report that using cellular mechanophenotyping, along with traditional methods such as immunostaining and genetic analysis, may provide a more comprehensive view of a tumor.
Hsueh-Chia Chang, the Bayer Professor of Chemical and Biomolecular Engineering, said technology his lab developed for other uses could easily be extended to apply to testing for the coronavirus.
Rutgers engineers have created a tabletop device that combines a robot, artificial intelligence and near-infrared and ultrasound imaging to draw blood or insert catheters to deliver fluids and drugs. Their research results, published in the journal Nature Machine Intelligence, suggest that autonomous systems like the image-guided robotic device could outperform people on some complex medical tasks.
Pixcell’s HemoScreen™ is a portable cartridge-based platform. It is fast, simple to use, and a cost-effective means of providing crucial diagnostic information, near patient, where it is needed most.
ELISA assay performed in pipette tips simplifies procedure and lowers cost Scientists have taken a common, yet laborious lab test and redesigned it to be performed in small 3D printed pipette tips used to measure and transfer fluids in the…